Engineering Transferrin-Decorated Pullulan-Based Prodrug Nanoparticles for Redox Responsive Paclitaxel Delivery to Metastatic Lung Cancer Cells

Paclitaxel (PTX) remains a cornerstone in the treatment of locally advanced and metastatic lung cancer. To improve its therapeutic indices against lung cancer, novel redox-sensitive pullulan/PTX-based prodrug NPs (PULL-SS-PTX NPs) were accomplished, which were further surface -decorated with transferrin (TF), a cancer cell-targeting ligand, to afford TF- PULL-SS-PTX NPs. These prodrug NPs (drug content, >37% and average size, 134-163 nm) rapidly dismantled their self-assembled architecture upon exposure to simulated reducing conditions, causing a triggered drug release as compared to the control scaffold (PULL-CC-PTX NPs). These scaffolds also evidenced outstanding colloidal stability, cellular uptake efficiency, and discriminating cytotoxicity between the cancer and healthy cells. Intravenously delivered redox-sensitive NPs exhibited improved tumor-suppressing properties as compared to the control nanovesicles (PULL-CC-PTX NPs) in a B16- F10 melanoma lung metastasis mice model. The targeting efficiency and associated augmented anticancer potentials of TF-PULL-SS-PTX NPs relative to TF-free redox-responsive NPs and Taxol intravenous injection were also established on the transferrin receptor (TFR) overexpressed Lewis lung carcinoma (LLC-luc) cell -bearing mice model. Moreover, the TF-functionalized scaffold displayed a reduced systemic toxicity compared to that of Taxol intravenous injection. Overall, the proposed TF-decorated prodrug NPs could be a promising nanomedicine for intracellular PTX delivery against metastatic lung cancer.

Automated summary

To improve the effectiveness of paclitaxel in treating lung cancer, novel redox-sensitive prodrug nanoparticles were developed, which were surface-decorated with transferrin for targeted delivery. These nanoparticles rapidly released the drug under reducing conditions and exhibited excellent stability, cellular uptake efficiency, and selective toxicity towards cancer cells. In animal models, the transferrin-decorated nanoparticles showed superior tumor-suppressing properties compared to the control nanoparticles and intravenous injection of paclitaxel. Moreover, they demonstrated reduced systemic toxicity. Overall, these transferrin-decorated nanoparticles hold great promise for the intracellular delivery of paclitaxel against metastatic lung cancer.